Published in Ter Arkh on January 01, 2004
[Dynamic changes in synovitis activity after intra-articular administration of xefocam in patients with rheumatoid arthritis (according to clinical and device examinations)]. Ter Arkh (2003) 0.84
[Antibodies to various phospholipids in SLE patients with primary antiphospholipid syndrome]. Klin Med (Mosk) (1999) 0.81
[Madecassol treatment of systemic and localized scleroderma]. Ter Arkh (1998) 0.79
[Cardiovascular diseases in rheumatoid arthritis]. Ter Arkh (2007) 0.77
[Clinical implication of assessment of heart rate variability in patients with psoriatic arthritis]. Ter Arkh (2009) 0.77
[Serum nitrates in patients with systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2004) 0.77
Anti-plasminogen autoantibodies from plasma of patients with systemic lupus erythematosus having anti-phospholipid antibody syndrome: isolation and some immunochemical properties. Biochemistry (Mosc) (2003) 0.77
[Role of antiphospholipid antibodies in occlusion of retinal vessels in various vascular eye diseases]. Vestn Oftalmol (2002) 0.77
[Cardiological aspects of the antiphospholipid syndrome. Part I. Valvular lesions in the primary and secondary antiphospholipid syndrome and systemic lupus erythematosus]. Kardiologiia (2002) 0.77
[The local therapy of enthesitis and bursitis of the calcaneal area in seronegative spondylarthritis]. Ter Arkh (1997) 0.76
[Antibodies to beta2-glycoprotein I in systemic lupus erythematosus: new laboratory marker of antiphospholipid syndrome]. Klin Med (Mosk) (1998) 0.76
[Sneddon's syndrome and the primary antiphospholipid syndrome]. Ter Arkh (1993) 0.76
[Soluble CD40 ligand in systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2006) 0.76
[Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome]. Ter Arkh (2008) 0.76
[Place of hemocarboperfusion and hyperbaric oxygenation in the treatment of patients with rheumatoid arthritis with systemic symptoms]. Ter Arkh (1986) 0.75
[Cardiolipin antibodies dependents on beta2-glycoprotein-1 in antiphospholipid syndrome]. Ter Arkh (1999) 0.75
[Vascular symptoms of Behcet's disease]. Ter Arkh (2005) 0.75
[Cardiovascular risk in psoriatic arthritis]. Ter Arkh (2009) 0.75
[Vasculopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome]. Ter Arkh (1995) 0.75
[Arterial hypertension and the antiphospholipid syndrome]. Ter Arkh (1996) 0.75
[An assessment of tissue microcirculation in patients with aseptic femur head necrosis in rheumatoid arthritis]. Ter Arkh (1994) 0.75
[Microcirculatory disorders in vasculitis of the skin]. Vestn Dermatol Venerol (1984) 0.75
[Treatment of Raynaud's syndrome with calcium entry blockers]. Ter Arkh (1987) 0.75
[Use of laser Doppler flowmetry in various rheumatic diseases]. Revmatologiia (Mosk) (1988) 0.75
[Soluble adhesion molecules in antiphospholipid syndrome associated with systemic lupus erythematosus and in primary antiphospholipid syndrome]. Ter Arkh (2002) 0.75
[Assessment of tissue microcirculation in patients with aseptic necrosis of femur heads in systemic lupus erythematosus (SLE)]. Ter Arkh (1999) 0.75
[The vasoprostan treatment of patients with Raynaud's syndrome]. Ter Arkh (1997) 0.75
[Atheroscleotic vascular lesion in systemic lupus erythematosus and antiphospholipid syndrome in men]. Klin Med (Mosk) (2006) 0.75
[Lipoprotein(a) in systemic lupus erythematosus]. Klin Med (Mosk) (1998) 0.75
[Morphologic features of the gastric mucosa in systemic lupus erythematosus and antiphospholipid syndrome]. Arkh Patol (2004) 0.75
[The condition of peripheral arteries in patients with systemic lupus erythematosus]. Klin Med (Mosk) (2004) 0.75
[Status of tissue microcirculation in psoriatic arthritis]. Ter Arkh (1986) 0.75
[Methods for the instrumental diagnosis and verification of Lyme arthritis]. Ter Arkh (1997) 0.75
[Comparative evaluation of tissue microcirculation in patients with aseptic necrosis of the femur head in rheumatoid arthritis and systemic lupus erythematosus]. Ter Arkh (2001) 0.75
[Antiphospholipid syndrome (Hughes syndrome): 10 years of study in Russia]. Klin Med (Mosk) (1998) 0.75
[Comparative evaluation of the treatment of Sjögren's syndrome with anti-rheumatic preparations]. Ter Arkh (1988) 0.75
[Interleukin-18 in systemic lupus erythematosus: link with clinical symptoms and vascular atherosclerosis]. Ter Arkh (2008) 0.75
[Vascular pathology in antiphospholipid syndrome]. Arkh Patol (2002) 0.75
[Antibodies to low density oxidated lipoprotein and ischemic cerebrovascular disorders in young patients]. Ter Arkh (1998) 0.75
[Clinical significance of the assessment of cardiac rhythm variability in patients with rheumatoid arthritis]. Klin Med (Mosk) (2009) 0.75
[Significance of bone marrow endothelial progenitor cells in disturbance of angiogenesis and endothelial dysfunction in systemic scleroderma]. Vestn Ross Akad Med Nauk (2008) 0.75
[Atherosclerotic lesion of the vessels in systemic lupus erythematosus in males: relations with concentration of C-reactive protein]. Ter Arkh (2005) 0.75
[Clinico-immunological aspects of antiphospholipid syndrome]. Vestn Ross Akad Med Nauk (2003) 0.75
[Corticosteroids in the treatment of secondary antiphospholipid syndrome]. Klin Med (Mosk) (2002) 0.75
[The lipid-protein indices of the blood cholesterol transport system in systemic lupus erythematosus]. Ter Arkh (1999) 0.75
[Cryoglobulinemia in Sjögren's syndrome]. Ter Arkh (1990) 0.75
[Microcirculatory disorders in patients with psoriatic arthritis]. Ter Arkh (1991) 0.75
[The clinical instrumental characteristics of the locomotor involvement in patients who have had Lyme disease]. Ter Arkh (1995) 0.75
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age]. Zh Nevrol Psikhiatr Im S S Korsakova (1997) 0.75
[Mutation of a 5,10-methylenetetrahydrofolate reductase gene in systemic lupus erythematosis and antiphospholipid syndrome]. Ter Arkh (2002) 0.75
[Hemodynamics and tolerance to physical exertion in patients with acute rheumatism]. Ter Arkh (1983) 0.75
[Clinico-instrumental evaluation of the laser therapy of rheumatoid arthritis]. Revmatologiia (Mosk) (1984) 0.75
[Relationship between the intima-media complex thickness, the risk factors of cardiovascular diseases, and the level of C-reactive protein in gouty patients]. Ter Arkh (2009) 0.75
[Comparative clinico-immunologic and microcirculation studies in families of patients with type 1 diabetes mellitus and systemic lupus erythematosus]. Vestn Akad Med Nauk SSSR (1989) 0.75
[Endothelial antibodies in Sneddon's syndrome]. Ter Arkh (1996) 0.75
[Levels of thromboxane and prostacyclin in patients with systemic lupus erythematosus and antiphospholipid syndrome]. Klin Med (Mosk) (1994) 0.75
[Articular lesions in Ixodes tick-borne borreliosis (Lyme disease)]. Vestn Ross Akad Med Nauk (2003) 0.75
[Differential diagnosis of diffuse eosinophilic fasciitis]. Revmatologiia (Mosk) (1990) 0.75
[Therapeutic principles in systemic lupus erythematosis with phospholipid syndrome]. Ter Arkh (1998) 0.75
[Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)]. Ter Arkh (1985) 0.75
[Endothelial dysfunction in scleroderma systematica: clinicopathogenetic correlations]. Ter Arkh (2008) 0.75
[Primary antiphospholipid syndrome in combination with heterozygous mutation in prothrombin (G20210A) gene: a case report]. Klin Med (Mosk) (2002) 0.75
[The late diagnosis of systemic lupus erythematosus with the antiphospholipid syndrome]. Ter Arkh (1997) 0.75
[The use of Vasaprostan in patients with systemic lupus erythematosus and the antiphospholipid syndrome]. Ter Arkh (1999) 0.75
[Osteonecroses in systemic lupus erythematosus and antiphospholipid syndrome]. Klin Med (Mosk) (2004) 0.75
[Leiden, G20210A mutations in prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2000) 0.75
[Sneddon syndrome new clinical and immunological data]. Klin Med (Mosk) (1998) 0.75
[Antibodies to beta2-glycoprotein I and antibodies to cardiolipin in antiphospholipid syndrome: analysis of sensitivity and specificity]. Klin Med (Mosk) (2003) 0.75
[Antiphospholipid syndrome: serological markers, diagnostic criteria, clinical manifestations, classification, prognosis]. Ter Arkh (1998) 0.75
[Extracorporeal therapy (hemosorption, plasmapheresis) in the combined treatment of severe forms of Sjögren's disease]. Vutr Boles (1988) 0.75
[Antiphospholipid antibodies in Behcet's disease]. Klin Med (Mosk) (2000) 0.75
[Soluble receptors of TNF-alpha: association with atherosclerotic vascular affection in systemic lupus erythematosus in males]. Ter Arkh (2006) 0.75
[Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up]. Ter Arkh (2003) 0.75
[The significance of cardiovascular risk factors and C-reactive protein to the development of atherosclerosis in women with systemic lupus erythematosus]. Klin Med (Mosk) (2006) 0.75
[Soluble CD40 ligand in systemic lupus erythematosus: link with atherosclerotic vascular affection]. Ter Arkh (2008) 0.75
[Muscular pathology in rheumatoid arthritis: a clinico-morphological study]. Klin Med (Mosk) (1996) 0.75
[The cerebral blood circulation in patients with systemic lupus erythematosus and the antiphospholipid syndrome]. Ter Arkh (1994) 0.75
[Labilization of DNA structure of peripheral blood leukocytes in patients with systemic lupus erythematosus]. Vestn Ross Akad Med Nauk (1994) 0.75
[The role of suprasegmental and segmental autonomic disorders in the development of muscular syndrome of rheumatoid arthritis]. Ter Arkh (2002) 0.75
[Clinical significance of heart rate variability in patients with systemic lupus erythematosus]. Ter Arkh (2008) 0.75
[Oxidized low-density lipoprotein antibodies in systemic lupus erythematosus: their connection with phospholipid antibodies]. Klin Med (Mosk) (1997) 0.75
[Combined therapy of thrombocytopenia in SLE patient with antiphospholipid syndrome]. Ter Arkh (1998) 0.75
[Acute rheumatic polyarthritis in young men]. Ter Arkh (1991) 0.75
[Rheumatoid arthritis in combination with primary biliary liver cirrhosis]. Ter Arkh (2000) 0.75
[Blood vessels morphology in antiphospholipid syndrome]. Arkh Patol (2002) 0.75
[Catastrophic antiphospholipid syndrome: diagnosis and treatment]. Ter Arkh (2005) 0.75
[Effect of vazaprostan on microcirculation in patients with scleroderma systematic]. Ter Arkh (2000) 0.75
[Microcirculatory disorders in the genesis of sclerodermic nephropathy]. Ter Arkh (1986) 0.75
[Thrombo ASS in the prophylaxis of vascular disorders in antiphospholipid syndrome]. Klin Med (Mosk) (1999) 0.75